Literature DB >> 9796980

Effect of the combined treatment with 5-fluorouracil, gamma-interferon or folinic acid on carcinoembryonic antigen expression in colon cancer cells.

A Aquino1, S P Prete, J W Greiner, A Giuliani, G Graziani, M Turriziani, R De Filippi, G Masci, E Bonmassar, L De Vecchis.   

Abstract

5-Fluorouracil (5-FU) and human recombinant gamma-interferon (gamma-IFN) were found to increase the expression of carcinoembryonic antigen (CEA) in human cancer cells in vitro. In the present study, the antimetabolite was associated with gamma-IFN or folinic acid (FA), a biochemical modulator of cellular metabolism of 5-FU, able to increase its antineoplastic activity. Treatment of two human colon cancer cell lines (HT-29 and WiDr) with 5-FU + gamma-IFN resulted in an increase of CEA expression higher than that obtainable with both agents alone, although no synergistic effects were obtained. This was demonstrated in terms of: (a) mRNA transcripts (HT-29); (b) cytoplasm and membrane CEA protein levels detected by Western blot analysis (HT-29); and (c) plasma membrane reactivity determined by flow cytometry analysis (HT-29 and WiDr). Moreover, 5-FU + gamma-IFN increased HLA class I molecules in the HT-29 cell membrane over that obtainable with gamma-IFN alone. In contrast, both agents did not induce the expression of the costimulatory molecule B7-1. Treatment with FA enhanced the antitumor effect of 5-FU but not its ability to augment CEA expression. This suggests that the FA-sensitive biochemical mechanism of action of 5-FU is not involved in its effect on CEA expression. In vivo studies showed, for the first time, that 5-FU, alone or combined with gamma-IFN, increases the amount of CEA protein over controls, either in cancer cells or in peripheral blood of nude mice bearing HT-29 cells. These results could be of potential diagnostic and/or therapeutic value when CEA protein is the target of humoral or cell-mediated immunity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9796980

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  12 in total

1.  Influence of cytokines, monoclonal antibodies and chemotherapeutic drugs on epithelial cell adhesion molecule (EpCAM) and LewisY antigen expression.

Authors:  D Flieger; A S Hoff; T Sauerbruch; I G Schmidt-Wolf
Journal:  Clin Exp Immunol       Date:  2001-01       Impact factor: 4.330

2.  Overexpression of heat shock factor 1 inhibits butyrate-induced differentiation in colon cancer cells.

Authors:  Jiyang Cai; Ward G Kirlin; Yan Chen; Xuexian Yan; Dean P Jones; Alan C Sartorelli
Journal:  Cell Stress Chaperones       Date:  2006       Impact factor: 3.667

Review 3.  Enhancing efficacy of therapeutic vaccinations by combination with other modalities.

Authors:  James L Gulley; Ravi A Madan; Philip M Arlen
Journal:  Vaccine       Date:  2007-06-04       Impact factor: 3.641

Review 4.  The role of tregs in glioma-mediated immunosuppression: potential target for intervention.

Authors:  William Humphries; Jun Wei; John H Sampson; Amy B Heimberger
Journal:  Neurosurg Clin N Am       Date:  2010-01       Impact factor: 2.509

5.  Increased expression of CEA and MHC class I in colorectal cancer cell lines exposed to chemotherapy drugs.

Authors:  Shunroh Ohtsukasa; Satoshi Okabe; Hironori Yamashita; Takehisa Iwai; Kenichi Sugihara
Journal:  J Cancer Res Clin Oncol       Date:  2003-10-15       Impact factor: 4.553

6.  Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study.

Authors:  Amy B Heimberger; Wei Sun; S Farzana Hussain; Mahua Dey; Lamonne Crutcher; Ken Aldape; Mark Gilbert; Samuel J Hassenbusch; Raymond Sawaya; Bob Schmittling; Gary E Archer; Duane A Mitchell; Darell D Bigner; John H Sampson
Journal:  Neuro Oncol       Date:  2007-12-13       Impact factor: 12.300

7.  A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.

Authors:  Philip M Arlen; James L Gulley; Catherine Parker; Lisa Skarupa; Mary Pazdur; Dennis Panicali; Patricia Beetham; Kwong Y Tsang; Douglas W Grosenbach; Jarett Feldman; Seth M Steinberg; Elizabeth Jones; Clara Chen; Jennifer Marte; Jeffrey Schlom; William Dahut
Journal:  Clin Cancer Res       Date:  2006-02-15       Impact factor: 12.531

8.  Combining Vaccines with Conventional Therapies for Cancer.

Authors:  Philip M Arlen; Ravi A Madan; James W Hodge; Jeffrey Schlom; James L Gulley
Journal:  Update Cancer Ther       Date:  2007-03

9.  Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis.

Authors:  Alexander Gelbard; Charlie T Garnett; Scott I Abrams; Vyomesh Patel; J Silvio Gutkind; Claudia Palena; Kwong-Yok Tsang; Jeffrey Schlom; James W Hodge
Journal:  Clin Cancer Res       Date:  2006-03-15       Impact factor: 12.531

Review 10.  Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.

Authors:  Ravi A Madan; Philip M Arlen; Mahsa Mohebtash; James W Hodge; James L Gulley
Journal:  Expert Opin Investig Drugs       Date:  2009-07       Impact factor: 6.206

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.